Patients at the Forefront: Teva's Patient First Initiative Pushes for Affordable Healthcare Reform

Strategic Insights -

As the US struggles with the high costs of prescription medicines, real Americans share their stories of struggle and the need for patient-centric reform. Teva Pharmaceuticals USA has launched the "Patient First" initiative, a part of the Year of Affordable Healthcare campaign, to raise awareness and push for change. The initiative features personal stories like that of Rob Day, a father of two with a rare blood disorder, who cannot afford his life-saving medicine.

Key Takeaways:

  • The Patient First initiative highlights the struggles of patients across America, with a common thread of hope for meaningful healthcare reform.
  • Rob Day's story, one of many patient stories, chronicles the challenges of accessing affordable prescription medicines.
  • Debra Barrett, Senior Vice President of Teva Pharmaceuticals USA, emphasizes the importance of healthcare reform, saying "Their stories should remind Congress and the White House of what this debate is all about."
  • The Year of Affordable Healthcare campaign calls for federal legislators to enact reforms, including a competitive regulatory approval pathway for generic biologics to increase access to affordable and lifesaving medicines.
  • Teva's Year of Affordable Healthcare campaign recognizes the significant role that generic drugs play in providing competitive and more affordable healthcare.
  • The Patient First initiative is available at http://www.yearofaffordablehealth.com/patients, featuring real-life stories and videos like Rob's.
  • Rob's story demonstrates the significant cost of life-saving medicines, with his biologic medication costing $389,000 per year.
  • An FDA approval pathway for generic biologic drugs could lead to more affordable versions of these medicines, with potential savings of billions of dollars for the healthcare system.
  • The approval pathway is supported by the Obama Administration and many members of Congress, aiming to provide relief to patients like Rob and introduce innovative biologic medicines for diseases such as diabetes, multiple sclerosis, and cancer.